Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review

nti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review Case report (2819) Total Article Views Authors: Imashuku S, Hasegawa T, Kubo K, Nakato M, Shima M Published Date April 2011 Volume 2011:4 Pages 31 - 34 DOI: http://dx.doi.org/10.2147/IMCRJ.S19433 Shinsaku Imashuku1, Takeshi Hasegawa2, Kagekatsu Kubo2, Masaki Nakato2, Midori Shima3 1Division of Pediatrics and Hematology, 2Division of Internal Medicine, Takasago-Seibu Hospital, Takasago, Hyogo; 3Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan Abstract: Acquired anti-Factor V deficiency caused by inhibitor production is a rare coagulation disorder. Although this is a well known entity in the literature, choice of optimal treatment for an individual patient is difficult, given that no standard therapeutic measures are available because of rare incidence and various underlying diseases occurring in the elderly. An 88 year-old man treated for Hashimoto's disease was found to exhibit prolongation of both prothrombin time and activated partial thromboplastin time. Detailed study of coagulation factors revealed a deficiency of Factor V. Our patient's coagulation disorder resolved in two weeks with intravenous administration of prednisolone 20 mg/day. Clinical features of autoimmune disease-related Factor V deficiency are discussed, along with eight previously reported cases over the past 20 years.